Changes in Registrant's Certifying Accountant

Business Context and Reporting Period

This Form 8-K Current Report was filed by Damora Therapeutics, Inc. (DMRA) on April 17, 2026. The filing addresses a change in the Company's independent registered public accounting firm.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it notes that the audit report for the fiscal year ended December 31, 2024, contained an explanatory paragraph regarding the Company's ability to continue as a going concern. The reports for fiscal years 2024 and 2025 did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.

Material Changes

  • Dismissal of Auditor: On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab ("EY Denmark") as the independent registered public accounting firm, effective immediately. EY Denmark had served the Company since 2019.
  • Appointment of New Auditor: On April 17, 2026, the Audit Committee engaged Ernst & Young LLP ("EY US") as the new independent registered public accounting firm, effective immediately.
  • No Disagreements: The Company reported no disagreements with EY Denmark on accounting principles, practices, or auditing scope during the two most recent fiscal years or the interim period through April 17, 2026.

Outlook, Risks, and Management Commentary

The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the historical note regarding the going concern qualification in the 2024 audit report. The transition of auditors from a Danish entity to a US entity (EY US) suggests a strategic shift in financial reporting oversight, though the filing states no consultations occurred with EY US regarding accounting principles or audit opinions prior to engagement.

Investor Verification Checklist

  • Verify the reasons for the auditor change by reviewing the letter from EY Denmark filed as Exhibit 16.1.
  • Review the most recent 10-K or 10-Q filings to assess the current status of the "going concern" qualification noted in the 2024 audit report.
  • Confirm the impact of the auditor transition on the timing of future financial statement releases.
  • Check for any subsequent filings that may elaborate on the strategic rationale for switching from EY Denmark to EY US.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.